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Considering the central role of inflammation in the pathogenesis of periodontitis, the combination 
of NSPT with different agents that can modulate the host immune‑inflammatory response has been 
proposed to enhance the outcomes of NSPT. The aim of this paper is to systematically review the 
literature on the efficacy of systemic host modulators (HMs) as adjuncts to non‑surgical periodontal 
therapy (NSPT) in improving pocket depth (PD) reduction and clinical attachment level (CAL) gain in 
healthy and systemically compromised patients. RCTs with ≥ 3 months follow‑up were independently 
searched by two reviewers. Meta‑analysis was performed when ≥ 3 studies on the same HM were 
identified. The quality of the evidence was rated according to the GRADE approach to rate the 
certainty of evidence. 38 articles were included in the qualitative assessment and 27 of them 
were included in the meta‑analysis. There is low/very low evidence that the adjunctive use of sub‑
antimicrobial dose of doxycicline, melatonin and the combination of omega‑3 and low dose aspirin 
(in type 2 diabetic patients) to NSPT would improve PD and/or CAL. Conflicting evidence is available 
on the efficacy of probiotics. Future studies controlling for confounding factors, using composite 
outcomes to define the endpoint of therapy and considering not only the patient‑ but also as the site‑
specific effect of systemic HMs are warranted. The dosage, posology and long‑term effect of HMs still 
need to be clarified, also in association to the presence of systemic conditions potentially affecting the 
response to HMs administration.
Periodontitis is a biofilm-induced chronic inflammatory disease of the tooth-supporting tissues. It has been 
extensively demonstrated that, while the tooth-associated microbial biofilm is essential to develop the disease, 
the desctruction of the periodontium is caused by the exaggerated immune-inflammatory host response to the 
microbial  challenge1.
Recent advancements coming from independent microbiology studies support a new model in the patho-
genesis of periodontitis, namely the polymicrobial synergy and dysbiosis (PSD) model. According to PSD the 
disease is initiated by a broadly-based dysbiotic and synergistic microbiota, where keystone species (such as P. 
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gingivalis) play an important role in triggering the  disease2. These microorganisms, even at low abundance, are 
able to engage in a two-way communication with the microbial community inhabitants in order to both impair 
host immune surveillance and elevate the pathogenicity of the entire microbiota. Inflammation seems to drive 
the selection and enrichment of the periodontitis-associated microbiota, which is therefore defined as “inflam-
mophilic”3, meaning that their presence further sustains the periodontal inflammation.
The goal of periodontitis treatment is to resolve the gingival inflammation and restore periodontal health, 
ideally with a restitutio ad integrum of the damaged tissues and it always starts with the non-surgical peri-
odontal therapy (NSPT). In particular, the first step in therapy aims to guide a behaviour change in patients by 
motivating them to proper and effective oral hygiene and it also includes risk factors control. This phase should 
be implemented in all periodontitis patients, irrespective of their disease stage, to facilitate their compliance 
and it represents the foundation for an optimal treatment response and long-term outcomes. The second step 
of therapy aims at controlling (reducing/eliminating) the subgingival biofilm and calculus through subgingival 
manual instrumentation and needs to be followed for all periodontitis patients, irrespective of their disease stage, 
for all teeth with loss of periodontal support and/or periodontal pocket  formation4. Although NSPT has proven 
to be effective in reducing probing pocket depths and improving clinical attachment  level5,6, its predictability 
may vary in relation to different factors related to the site (e.g. pocket depth, furcation involvement), the patient 
(e.g. supragingival plaque control, maintenance care, concomitant systemic diseases, smoking) and the clini-
cian (e.g. effective removal of the biofilm, patient motivation)7. Hence, a third step of therapy may be required, 
which is aimed at treating those sites that did not adequately respond to the second stage of therapy (residual 
pockets ≥ 4 mm with bleeding on probing and deep pockets ≥ 6 mm) and it may include the repetition of sub-
gingival instrumentation with or without adjunctive therapies and/or different types of periodontal  surgeries4.
Considering the central role of inflammation in inducing periodontal tissue breakdown and in selecting 
and sustaining the periodontitis-associated microbiota, the combination of NSPT with different agents that can 
modulate the host immune-inflammatory response has been proposed to further enhance the outcomes of NSPT, 
thus possibly reducing the need for subsequent surgeries. A range of host modulating agents that can either block 
the immune-inflammatory response or promote the natural resolution of the inflammation has been investigated 
in the past years with heterogeneous results.
The present systematic review aimed to critically evaluate the efficacy of systemic host modulators as adjunc-
tive therapy to NSPT in light of the most recent evidence and to complement the recent review by Donos et al.8 
by also informing on the short-term effect (3 months) of host modulators and on their use in systemically com-
promised patients to provide a comprehensive evidence-based guidance for clinicians following the Grading 
Recommendations Assessment, Development and Evaluation (GRADE) system with the aim of knowing how 
much confidence we can have in the results of the review.
Methods
The study protocol was registered in PROSPERO (http:// www. crd. york. ac. uk/ PROSP ERO) with the registration 
number CRD42018088683 in February 2018, before the beginning of the research.
The protocol is compliant with the Cochrane  Handbook9 and the results were presented following the instruc-
tions of the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA)  statement10.
PICO question. In human subjects with any form of periodontitis, does the adjunctive use of host-modu-
lator drugs increase the clinical efficacy of non-surgical periodontal therapy (P: humans with periodontitis; I: 
non-surgical periodontal therapy plus systemically delivered host-modulator drugs; C: non-surgical periodontal 
therapy alone or combined with placebo; O: clinical outcomes (probing depth (PD) reduction, clinical attach-
ment level (CAL) gain)?
Search strategy. The following electronic databases were searched for pertinent papers: MEDLINE / Pub-
Med, Scopus, ISI Web of Science, EMBASE and Cochrane Central using a search strategy presented in Appendix 
1. Grey literature was searched for pertinent articles interrogating Greylit and OpenGrey. A manual search of 
the reference lists of the included papers and of the table of contents (since 1990) of Journal of Clinical Peri-
odontology, Journal of Periodontology, Journal of Periodontal Research, Journal of Dentistry, Journal of Dental 
Research was also performed. Conference abstracts were excluded and only articles in English were considered. 
The last electronic search was performed on 12th April 2020. A two-stage screening process (titles and abstract 
first followed by full-text) was performed by two independent reviewers (SC, EC).
Inclusion criteria. 
1. Types of studies included: randomized controlled clinical trials with at least 3-month follow-up calculated 
from the beginning of the treatment protocol
2. Study population: adult (≥ 18 years old) patients affected by periodontitis, either systemically healthy or 
systemically compromised (e.g. with type 2 diabetes mellitus)
3. Intervention: Test group—NSPT protocol (including mechanical treatment using manual curettes and / 
or ultrasonic devices without the use of antimicrobial agents) combined with the use of a systemic host 
modulator including but not limited to non-steroidal anti-inflammatory drugs (NSAIDs), bisphosphonates, 
unsaturated fatty acids, statins, sub-antimicrobial dose of doxycycline, probiotics, micronutrients, melatonin; 
Control group—the same NSPT protocol alone or associated with a placebo
4. Outcomes: Primary outcome—reduction in probing depth (PD) and/or clinical attachment loss (CAL) col-
lected at patient level. The primary outcomes can be referred to all the teeth in the mouth or to all the teeth 
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with periodontal pockets (PD > 4 mm); Secondary outcomes—changes in plaque scores, bleeding/inflamma-
tion scores, adverse events and patient-reported outcome measures (PROMs)
The studies had to provide a complete description of the host modulator prescribed, meaning the presentation 
of the active substance, concentration and dosage in order to be considered for this review.
Studies with a split-mouth design, and studies presenting data only on a sample of the teeth were excluded. 
Studies reporting duplicated data (the same data published elsewhere) were excluded.
Cohen’s kappa served to evaluate the concordance in the selection of the two authors.
Disagreements in article selection processes were solved by consulting a third reviewer (AA) whose opinion 
was considered diriment.
Data extraction. Three authors (SC, EC, AA) independently extracted the following data from the included 
studies: author names, year of publication, country of recruitment and treatment, sample characteristics (size, 
ethnicity, gender distribution, smoking status, mean age or age groups), definition / diagnostic criteria of perio-
dontal disease, clinical data before and after the treatment (mean periodontal probing depth (PD), mean clinical 
attachment level (CAL), gingival bleeding indexes (Gingival Bleeding  index11, Gingival index-GI—12, percentage 
of bleeding sites—BOP -), plaque indexes (Plaque  index13, Turesky-modified plaque  index14, proportion of sites 
with visible plaque) or difference between baseline and follow-up values. The occurrence of adverse events and 
all patients’ reported outcomes (PROMs) were recorded.
An attempt was made to contact by email the authors of the papers providing insufficient information.
Risk of bias evaluation. The risk of bias evaluation and quality assessment of all included papers was 
performed by two reviewers (SC, AA) and any disagreement was resolved by discussion. The criteria considered 
for risk of bias evaluation were extrapolated from the Cochrane Handbook for Systematic Reviews9 (Cochrane 
risk-of-bias tool for randomized trials) and they included:
• Bias arising from the randomization process
• Bias due to deviations from intended interventions
• Bias due to missing outcome data
• Bias in measurement of the outcome
• Bias in selection of the reported result
The overall risk-of-bias judgement was high risk if the level of risk of bias was judged to be high for at least 
one domain or if the trial was judged to have some concerns for multiple domains (three). If the trial was judged 
to have some concerns for less than three domains the overall risk of bias was “some concerns”, while the study 
was judged to have low risk of bias if all domains were judged to have low risk.
The funding bias was estimated by evaluating if authors disclosed their potential sources of competing conflict 
of interest and the source of funding for the studies they carried on (if any).
Meta‑analysis, assessment of heterogeneity and assessment of reporting biases. For quan-
titative analysis, studies were grouped according to the HM employed, follow-up time and, whenever possible, 
according to the initial PD. Meta-analysis was performed using the software RevMan (Review Manager Version 
5.3, 2014; The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark) if at least three 
papers were available for each comparison. A sub-analysis was performed when three or more studies were 
available for one specific active principle within the same category of HMs (e.g. ibuprofen among FANS or one 
specific probiotic).
For each presented outcome, the difference between baseline and follow-up values were extracted (with spe-
cific error measure such as standard deviation (SD) or standard error (SE) or variance). When such parameter 
was not presented, it was computed as the difference between baseline and follow-up values. In these cases, 
following the instructions of the Cochrane Handbook for Systematic Reviews when SDs of changes values were 
not presented and they were not provided by authors after contacting them by email, they were computed as 
follows: (1) if similar studies were present (similar treatment, similar population, similar sample size), SD was 
imputed taking the value of the other study; (2) when P value is presented SD was computed by using T tables 
for retrieving SEs; (3) when P value is presented as a limit (e.g. < 0.05) a conservative value of P (e.g. 0.05 in case 
of < 0.05) was considered for computing SE as described before; (4) if P value was not present SDs of change 
values was imputed by using the following  formula9,15,16:
being CORR the correlation coefficient, that could be imputed from similar studies if present, or it was assumed 
conservatively to be 0.2. For each measure, pooled estimate of 95% CI was calculated.
In the meta-analysis effect size was computed through the weighted mean method and results were combined 
using the DerSimonian and Laird’s random-effect  model17, assuming heterogeneity among studies.
Cochran’s test served to measure the consistency of the results, considering it significant if P < 0.1.  I2 statistics 
was applied to measure heterogeneity (total variation across studies that was due to heterogeneity rather than to 
chance). If  I2 was less than 40% the heterogeneity was negligible, if it was from 40 to 60% it signified a moderate 
SDcv =
√
SD baseline2 + SD final2 −
(
2 ∗ CORR ∗ SD baseline ∗ SD final
)
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heterogeneity, if 60% to 90% it signified a substantial heterogeneity while it showed a considerable heterogeneity 
if it was from 75 to 100%18.
Small study effects, as proxy for publication bias, were assessed by testing for funnel plot asymmetry and by 
calculating Egger´s bias, as described in the Cochrane Handbook (Higgins and Green 2011).
Quality of evidence assessment. The quality of the available evidence was assessed for each comparison 
and for each outcome included in the meta-analysis through the Grading of Recommendations, Assessment, 
Development and Evaluations (GRADE) approach. GRADE provides a system for rating quality of evidence 
and strength of recommendations that is explicit, comprehensive, transparent, and  pragmatic19. More specifi-
cally, GRADE indicates four grades of evidence (high quality, moderate, low, and very low) and the strength of 
recommendation is qualified as strong, weak, or conditional to an intervention (pro or con) for each specific 
comparison and outcome. The GRADE approach implies the consideration of the risk of bias of the studies, of 
inconsistency (heterogeneity), of indirectness of evidence, of imprecision of the effect estimates and of risk for 
publication bias.
Results
The article selection process is summarized in Fig. 1. The electronic and manual search retrieved a total of 3884 
papers, whose titles and abstract were assessed for eligibility. A total of 150 full text articles were checked for 
inclusion. Of those, a total of 38 articles were included in the qualitative assessment and 27 of them were included 
in the meta-analysis. Kappa of agreement during the selection process was > 0.9 for titles and abstracts, as well as 
for full texts. Reasons for exclusions of studies at the full-text stage are reported in Appendix 2. 
The studies included were published from 2004 to 2020 and they were carried on in various countries, 25 of 
them in University settings, two in private practices, one in University and private setting and the others did not 
provide any information about the setting.
The summary of the characteristics of the included studies are presented in Table 1. Briefly, eight out of 38 
studies did not have a placebo control group (17.9%), and five had two test groups. With regard to the char-
acteristics of the population, one study examined a sample made only of postmenopausal  women20, one was 
on elderly people (≥ 65 years old)21, four studies on former or current  smokers22–25, and one study included 
only smokeless tobacco  users26. For systemically compromised patients five studies included only subjects with 
treated type 2  diabetes27–30, and the other studies were on systemically healthy subjects. The maximum reported 
follow-up was 12 months. 
Risk of bias. The results of the risk of bias evaluation for studies involving healthy and systemically compro-
mised subjects are shown in Appendix 3. Briefly, the evaluation of 17 out of 38 studies (43.6%) raised some con-
cerns about the risk of bias, while the others (56.4%) were judged to be at low risk. The main concerns about the 
risk of bias evaluation were due to inadequate description of the randomization and allocation methods (16 of 38 
studies, 41.0%), the number of dropouts (3 of 38 studies, 7.7%), and the absence of the placebo (8 of 38 studies, 
20.5%), which might have influenced the awareness of the patient of their assigned intervention. Twenty of the 
included papers reported that they were supported in different forms (financial support, grant or the products) 
by manufacturers of the host modulators tested.
Synthesis of the results. The summary-of-findings tables are presented in Appendix 4.
Omega‑3. Omega-3 (PUFA n-3) were tested in four  studies31–34, where the host modulator was administered 
with different prescriptions and doses (EPA 180 mg / DHA 120 mg once a day for 3 months; EPA 6.25 mg + DHA 
19.19 mg twice a day for 6 months; Omega-3 fatty acids 500 mg twice a day for 90 days; PUFAs 300 mg once a 




Owing to the limited number of studies, meta-analysis combined data from healthy  patients31,32 and patients 
affected by type 2  diabetes33 and results are presented in Table 2. The differences between the test and the 
control groups were not statistically significant for PD and CAL. The certainty of the available evidence 
(GRADE) was rated as very low (Appendix 5). Another study not included in the meta-analysis in healthy 
subjects reported that dietary supplementation of Omega-3 had no benefit on clinical parameters.
Secondary outcomes
When combining data from  healthy31,32 and diabetic type 2  patients33, no significant improvement in GI were 
observed between the test and the control groups (Table 2).
Plaque levels, reported in the study by Deore et al.31, improved significantly in both groups, without any 
significant difference between them. Two studies on healthy patients indicated that dietary supplementation 
of Omega-3 reduced the levels of TNF-α34 and of IL-1beta32.
None of the studies reported the occurrence of any complication or adverse events.
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Systemically compromised patients. 
Primary outcomes
No significant differences in PPD and CAL at 3 months of healing were observed when omega-3 or a placebo 
were administered together with  NSPT33.
Secondary outcomes
In diabetic patients, plasma level of pentraxin (PTX3) improved significantly more when omega-3 rather than 
low-dose aspirin or placebo were combined with  NSPT33.
Omega‑3 and acetylsalicylic acid. PUFA n-3 were combined with acetylsalicylic acid (ASA) in two studies, 
which were both on diabetic type 2 patients treated with hypoglycemic drugs and/or  insulin28,30. The doses of 
ASA varied from 75 to 100 mg daily for up to 6 months.
Healthy patients. The literature search did not identify any RCT where NSPT was combined with Omega-3 
and ASA in healthy patients.
Figure 1.  Study flow diagram.
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characteristics N° subjects Sex
Age 






Ethnicity Periodontal disease Outcomes
Type of 
probe and N 
sites/tooth 
evaluated NSPT details Follow-up
Negative 
control group 
(G0) Test group 1 (G1) Test group 2 (G2)
Rocha et al. 
(2004) RCT 40 40F
55–65; G0: 







At least 3 teeth with 
PD ≥ 3 mm, GI of 2 or 
3, PI 2 or 3, gingival 
recession, and a mini-


















O; 6 sites per 
tooth
SRP in 4 
sessions
6 mo from 
beginning of 





NSPT + Alendronate 














CP: at least 4 teeth 
with PD of 5–9 mm 
in 3 or 4 qualifying 
quadrants
CAL, PD, GCF 
levels, MMP-8 
















1, 3, 6, 9 mo NSPT + pla-cebo (ND)
NSPT + Doxycycline 






















5 Asian, 9 
Hispanic
CAL and PD between 
5 and 9 mm with 







probe, 6 sites 
per tooth
SRP performed 




3, 6, 9 mo NSPT + pla-cebo (ND)
NSPT + doxycycline 

















CP: CAL 5–9 mm, 
PD 4–9 mm and 











3, 6, 9 mo NSPT + pla-cebo (ND)
NSPT + doxycycline 
hyclate 20 mg twice a 































by a single 
operator
3 mo NSPT alone
NSTP + Doxycycline 










47.70 ± 7.59 
(35–61); G1: 
46.11 ± 6.37 
(34–59)
Not heavy 




At least 8 sites with 
PD ≥ 5 mm and 
CAL ≥ 4 mm, and 
radiographic evidence 
of moderate to 
advanced CP (Armit-
age 1999)
PD, CAL, GI 
(Löe and Sil-






probe; 6 sites 
per tooth
SRP in 4–6 
sessions, 
performed 
by a single 
operator
3, 6, 9, 12 
mo from 
beginning of 







NSPT + Doxycycline 



















(10 + cigarettes 
per day for at 
least 1 year)
NS
CP: at least two teeth 
with PD ≥ 6 mm and 
at least 2 quadrants 
(excluding third 
molars) with bone 
loss ≥ 30%
CAL, PD, REC 
(only sites 
with initial 




probe, 6 sites 
per tooth
SRP + OHI 
in 4 sessions, 
performed 
by a single 
experienced 
periodontist, 













NSPT + 20 mg 
doxycycline twice a 












49.9 ± 11.0 
(23–82); G1: 
48.5 ± 11.4 
(24–81) (of 
266)









7 Asian, 5 
other (of 
266)
At least 4 periodontal 
sites in each of 2 
quadrants, at least 
2 affected teeth 
per quadrant, all 
8 qualifying sites 
with PD ≥ 5 mm, 
CAL ≥ 5 mm, and 
BOP score ≥ 1, at least 




















3, 6, 9 mo NSPT + pla-cebo (ND)
NSPT + doxycycline 
40 mg once a day 
for 9 mo
–




131 (101, 85, 
74 and 65 at 




48.6 ± 9.94; 
G0: 47.3 ± 9.2; 
G1: 





24 Black, 4 
Hispanic, 
7 Asian, 2 
other (at 3 
mo)
At least 4 teeth with 
PD > 4 mm and 
CAL > 2 mm, and at 











probe, 6 sites 
per tooth
SRP in 2 
sessions within 
1–2 weeks




NSPT + Celecoxib 































probe, 6 sites 
per tooth













3, 6 mo NSPT alone
NSPT + neridronate 





















CP: at least 2 
non-adjacent sites 
per quadrant that 
are not first molar 
or incisor, with 
PD ≥ 5 mm + bleeding 
on gentle prob-
ing + radiographic 
bone loss ≥ 30% of the 




















1, 3 mo NSPT alone
NSPT + Vitamin C 






blind, parallel 34 16 M, 18F
G0: 56.0 ± 9.0; 
G1: 57.6 ± 8.0
T2DM (at 




Severe or moderate, 
localized or general-
ized CP: at least 4 
non-adjacent sites 







probe; 6 sites 
per tooth
SRP in 1 
session, 
performed by a 
single operator 









NSPT + doxycycline 
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characteristics N° subjects Sex
Age 






Ethnicity Periodontal disease Outcomes
Type of 
probe and N 
sites/tooth 
evaluated NSPT details Follow-up
Negative 
control group 





61 (60 at 3 
mo, 54 at 6 
and 9 mo)
21 M, 39F
G0: 47.9 ± 6.6; 
G1: 48.3 ± 8.4; 





At least 2 sites per 
quadrant with PD 
or interproximal 
CAL loss > 6 mm and 
radiographic bone 
















6 sites per 
tooth
SRP in 4 ses-
sions within 1 
mo, performed 












NSPT + FV (declared 
totals per daily dose: 
b-carotene 7.5 mg, 
vitamin E 46 mg, 
vitamin C 200 mg, folic 
acid 400 lg) for 8 mo
NSPT + FVB 
(declared totals 
per daily dose: 
b-carotene 
7.5 mg, vitamin E 
66 mg, vitamin C 
222 mg, folic acid 

















Moderate to severe 




























by a single 
periodontist 






3, 6, 9 mo NSPT + pla-cebo (ND)
NSPT + Probiotic (L. 
reuteri 1E8 CFU) twice 


















moderate to advanced 
CP: at least 2 sites 
with PD ≥ 5 mm and 
BOP + ; CAL ≥ 5-mm; 
and radiographic evi-
dence of bone loss
PD, CAL, 
BOP









SRP in 4 ses-
sions at 1-week 
intervals, 
performed 
by a single 
experienced 
periodontist 




3 mo from 
beginning of 






NSPT + doxycycline 
























Moderate CP: at least 
2 interproximal sites 
with CAL ≥ 4 mm 
on different teeth 
or PD ≥ 5 mm on 
different teeth); 
Severe CP: at least 2 
interproximal sites 
with CAL ≥ 6 mm on 
different teeth and at 
least 1 interproximal 
site with PD ≥ 5 mm 
(Page and Eke 2007)
PD, CAL, SBI, 




probe, 4 sites 
per tooth




by a single 
periodontist, 











NSPT + omega-3 









CP: at least 2 
interproximal sites 
with CAL ≥ 4 mm, 
or ≥ 2 interproximal 
sites with PD ≥ 5 mm, 
not on the same tooth 











6 sites per 
tooth
SRP performed 




3 mo NSPT alone
NSPT + Vitamin E 
200 mg (300 IU) every 









G0: 47 ± 5 
(39–58); 






Moderate to severe 




PI (Silness and 
Löe 1964), 
















by a single 
periodontist 











except for the 
probiotic)
NSPT + probiotic (S. 
oralis KJ3, S. uberis KJ2 
and S. rattus JH145, at 
least  108 CFU of each 
strain per tablet) twice 










41.40 ± 8.86; 






horizontal bone loss; 
at least 2 teeth with 
one approximal site 
each with a PD of 
5–7 mm and GI ≥ 2 




ness and Löe 







NS sites per 
tooth
SRP in 2 ses-
sions at 1-week 
intervals, 
performed 








NSPT + Probiotic (L. 












42.20 ± 2.78; 




NS CP (Armitage 1999)
PD, RAL, 
%BOP, PI (Sil-
ness and Löe 





probe; 6 sites 
per tooth












NSPT + probiotic (L. 






blind, parallel 40 20 M, 20F




Moderate to severe 
CP: ≥ 14 natural 
teeth, at least 5 teeth 
with PD ≥ 5 mm and 
CAL ≥ 4 mm (AAP 
2000)
PD, CAL, 
GI (Löe and 
Silness 1963), 
PI (Silness and 
Löe 1964), 
GCF levels 







of sites per 
tooth




by a single 
periodontist, 









placebo for × 3 
PUFAs: 
coconut oil)
NSPT + omega-3 1 g 
3 times a day + 75 mg 





















CP: at least 5 teeth 
with PD ≥ 5 mm and 
CAL ≥ 3 mm, 20% 
BOP, and extensive 
radiographic bone 
loss (Pozo et al. 2005)
PD, CAL, %PI, 
%BOP
UNC-15 
probe, 6 sites 
per tooth
SRP in 4–6 ses-














NSPT + probiotic 
(L. rhamnosus SP1, 
2 ×  107 CFU/day) once 
a day for 3 mo
–
Continued
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characteristics N° subjects Sex
Age 






Ethnicity Periodontal disease Outcomes
Type of 
probe and N 
sites/tooth 
evaluated NSPT details Follow-up
Negative 
control group 












39.4 ± 21.6; 
G1: 34 ± 25.6
Systemically 
healthy NS
Moderate CP: at least 
2 interproximal sites 
with CAL ≥ 4 mm or 
PD ≥ 5 mm); Severe 
CP: at least 2 inter-
proximal sites with 
CAL ≥ 6 mm and at 
least 1 interproximal 
site with PD ≥ 5 mm
PD, CAL, 
















1, 2, 3 mo NSPT + pla-cebo (ND)
NSPT + Incyclinide 










G0: 43.5 ± 5.8; 
G1: 44 ± 6.44 Not smoking NS
At least 30% of 
the sites with 
CAL ≥ 5 mm (Flem-
mig 1999)
PD, CAL PI 
(Silness and 
Löe 1964), 
GI (Löe and 
Silness 1963), 
GBI (Ainamo 







1, 3 mo NSPT alone
NSPT + 700 mg fish oil 
(EPA 180 mg / DHA 




(2017) RCT 60 29 M, 31F 41 (23‒65) Not smoking Iranians
Moderate-to-severe 
CP: at least 3 sites 
with PD of 5–7 mm
PD, CAL, GI
UNC-15; 
4 sites per 
tooth
SRP performed 
by a single 
periodontist 




3, 6 mo NSPT alone NSPT + Melatonin 2 mg a day for 4 weeks
NSPT + Melatonin 
2 mg a day for 
4 weeks + Vitamin 
C 60 mg (females) 
or 75 mg (males) 
















CP: at least 9 
posterior teeth (not 
including third 
molars and teeth with 
bridges and crowns) 
with PD of 5–7 mm 
and 3 teeth with 
PD ≥ 6 mm







of TNF-α and 
SOD
Williams 
probe; 6 sites 
per tooth
SRP performed 
by a single 
experienced 
operator





except for the 
fish oil)
NSPT + omega-3 
PUFAs (EPA 












G0: 46.7 ± 8.3; 








loss and presence 
of PD ≥ 5 mm and 
at least 3 sites in 
each quadrant with 
CAL ≥ 4 mm (Armit-
age 1999)
PD, CAL, 
GI (Löe and 
Silness 1963), 
%BOP, PI 





SRP in 2 
sessions, 
performed 
by a single 
experienced 
periodontist 




3, 6 mo NSPT + pla-cebo (ND)
NSPT + melatonin 







































by a single 
periodontist 




1, 3 mo NSPT + pla-cebo (ND)
NSPT + Probiotic (B. 
lactis HN019, 109 
CFUs per lozenge) 











G0: 52.8 ± 7.5; 
G1: 46.5 ± 9.3; 











CP: at least 5 teeth 
with PD ≥ 4 mm and 
CAL ≥ 1 mm, 20% 
BOP, and extensive 
radiographic bone 










probe, 6 sites 
per tooth
SRP in 4–6 ses-













NSPT + probiotic 
(L. rhamnosus SP1, 
2 ×  107 CFU/ day) once 
a day for 3 mo
NSPT + antibiotic 
(Azithromycin 
500 mg) once a 
day for 5 days
Surapaneni 







CP: at least 4 teeth 
with PD ≥ 5 mm, 
CAL ≥ 4 mm and 




probe; 6 sites 
per tooth
SRP performed 
by a single 
operator






analysed) 35 M, 62 F
G0: 









Incipient to moderate 
generalized CP: PD of 
4–6 mm in at least 1 
site per quadrant
PD, CAL, 
PI, GI, REC, 
VAS
UNC-15; 
6 sites per 
tooth
SRP + OHI 
using the same 
toothbrush and 
toothpaste
3 mo NSPT + pla-cebo (ND)
NSPT + vitamin C 
150 mg + vitamin E 










CP: At least 4 teeth 
with PD ≥ 5 mm, 
CAL ≥ 4 mm (Machtei 
et al. 1992)
PD, CAL, GI Williams probe
SRP (no fur-





NSPT + aspirin 75 mg 
once a day for 90 days
NSPT + Omega-3 
fatty acids 500 mg 











54.1 ± 9.0; 






At least 2 non-
adjacent teeth with 
PD ≥ 5 mm and evi-
dence of radiographic 





6 sites per 
tooth
SRP + OHI 
in at least 
5 sessions, 
performed 




3, 6 mo 
from 
beginning of 





NSPT + Probiotics (L. 
reuteri 2E8 CFU) twice 





















CP: at least 6 
teeth with PD and 
CAL ≥ 5 mm and at 
least 40% of sites with 
PD and CAL ≥ 4 mm 





6 sites per 
tooth
SRP in 1 ses-
sion lasting 1 h, 
performed by 
two specialists 




3 mo NSPT + pla-cebo (ND)
NSPT + Probiotics 
450 mg (L. reuteri, 1E8 






blind 60 24 M, 36 F 57.0 ± 10.6
Systemically 
healthy Brazilian
Stage III or IV gener-
alized periodontitis, 





4 sites per 
tooth
SRP performed 
by a single 
operator both 




1, 2, 3 mo NSPT + pla-cebo (xylitol)
NSPT + xylitol + Pro-
biotics (L. reuteri 
 109 CFU / day; L. 
salivarius  109 CFU 
/ day; L. acidophilus 





masked, parallel 64 64 M
G0: 51.5 ± 2.4; 













by a single 
experienced 
operator, both 




3, 6 mo NSPT alone
NSPT + Probiotics (L. 
reuteri 2E8 CFU) twice 
a day for 21 days
–
Continued
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Systemically compromised patients. 
Primary outcomes
Owing to the limited number of studies, the meta-analysis could not be performed.
Remarkably, one  study30 found that 2-month administration of omega-3 plus ASA before or after NSPT 
increased the number and percentage of patients that reached the endpoint for treatment (≤ 4 pockets with 
PD ≥ 5 mm) compared to the control patients that only received NSPT and placebo, while the other study 
reported a highly significative difference (P ≤ 0.01) for values of PD and CAL at 3 and 6 months follow-ups 
between the test and the control  group28.
Secondary outcomes
While in one study inflammation scores (BOP% and GI) showed a similar improvement in the test and control 
groups, without significant inter-group  differences30, the other study found a statistically significant difference 
in GI between groups at 3 and 6  months28.
Dos Santos et al.30 showed that plaque level decreased significantly more when NSPT was combined with 
omega-3 plus low-dose aspirin for 2 months after NSPT. The authors also indicated that cytokine levels 
inversely correlated with periodontal parameters when adjunctive omega-3 PUFA and ASA therapy was 
administered, as opposed to the positive correlation detected in the placebo group.
Elwakeel and Hazaa reported nausea, abdominal upsets and irritating fish-scented halitosis in 13 out of 20 
subjects in the intervention  group28.
NSAIDs. Only 2 studies were identified, one in healthy subjects and one in type 2 diabetic patients, so no meta-
analysis could be performed.
Healthy patients. 
Primary outcomes
One study tested the effect of cyclooxygenase-2 inhibitor (Celecoxib 200 mg daily for 6 months) as an adjunct 
to NSPT in systemically healthy patients and it showed significant improvements in both PD and CAL in 
the test compared to the control  group35. This beneficial effect appeared to be more evident in pockets with 
baseline PD ≥ 7 mm, having PD reduced of 3.27 ± 1.56 mm in the test group and of 1.89 ± 1.60 mm in the 
control group after 3  months35.
Secondary outcomes
Plaque level and BOP decreased similarly in patients that received Celocoxib associated with NSPT or not.
The authors indicated no concerns about drug  safety35, and complications / adverse effects were not reported.
Systemically compromised patients. 
Primary outcomes
A recent study on adjunctive administration of ASA to NSPT in subjects with type 2 diabetes failed to dem-
onstrate a beneficial effect of this  HM33.
Secondary outcomes




characteristics N° subjects Sex
Age 






Ethnicity Periodontal disease Outcomes
Type of 
probe and N 
sites/tooth 
evaluated NSPT details Follow-up
Negative 
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G0: 54.9 ± 9.7; 
G1: 









CP: at least 6 
sites with PD and 
CAL ≥ 5 mm and 
BOP + (Armitage 
1999)
PD, CAL, 





SRP in 1 
session, 
performed 










3, 6 mo NSPT + pla-cebo (ND)
NSPT + Omega-3 
PUFAs 900 mg + ASA 
100 mg daily for 2 mo
Omega-3 PUFAs 
900 mg + ASA 
100 mg daily 




(2020) RCT, triple-blind 20 12 M, 8 F 45.6
Systemically 
healthy Italian
severe stage III 
periodontitis: 
at least 4 teeth 
with PD ≥ 6 mm, 
CAL ≥ 5 mm (Tonetti 
et al. 2018b)
























NSPT + Melatonin 
1 mg once a day 
per 1 mo
–
Table 1.  Main characteristics of the included studies. Abbreviations and references used in this table are 
reported in Appendix 6.
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Melatonin. Melatonin was studied as an adjunctive HM to NSPT in three  studies36–38 in systemically healthy 




The 6-month PD reduction was significantly different between the two groups (0.85 mm, 95%CI 0.46 mm 
to 1.24 mm), with high heterogeneity among the studies (Table 2). The certainty of evidence (GRADE) was 
very low (Appendix 5).
Secondary outcomes
In two studies, gingival bleeding level (BOP%), as well as plaque levels decreased similarly in both test and 
control  groups36,38.
In two studies few subjects reported minor adverse reactions, such as headache, dizziness, nausea, constipa-
tion, diarrhea, and abdominal cramp (2 cases)36,37.
Systemically compromised patients. The literature search did not identify any RCT where NSPT was combined 
with melatonin in systemically compromised subjects.
Biphosphonates. Two studies reported data about the systemic adjunctive administration of bisphosphonates 
(alendronate and neridronate) to NSPT in healthy  patients20,39, therefore no meta-analysis could be performed.
Healthy patients. 
Primary outcomes
One study assessed the adjunctive administration of 10 mg alendronate (for 6 months) in postmenopausal 
women, reporting significantly higher improvements in clinical parameters in the test group (PD reduction 
of 0.8 ± 0.3 mm and CAL gain of 0.99 ± 0.8 mm) than in the control group (PD reduction of 0.4 ± 0.4 mm and 
CAL gain of 0.5 ± 0.8 mm) at the 6-month follow-up20. Another study tested the adjunctive effect of 12.5 mg 
neridronate (once a week for 12 weeks) to  NSPT39, but no significant improvement was observed in the short 
term (6 months after the beginning of the treatment).
Secondary outcomes
In one study the authors reported a significant improvement in gingival bleeding (BOP%) in the test  group20, 
whilst another study did not find any difference in full-mouth bleeding values changes between  groups39.
In both studies, the improvement in plaque level was not affected by the administration of bisphosphonates.
In one study the authors reported that eight subjects in the test group experienced unspecified adverse 
 events39.
Systemically compromised patients. The literature search did not identify any relevant RCT where NSPT was 
combined with bisphosphonates in systemically compromised subjects.
Vitamins. Either vitamin complexes or single products were studied as adjunctive host modulators in four 
studies in healthy  patients40–43.
Healthy patients. 
Primary outcomes
No statistically significant differences were found for PD and CAL changes at 3 months of follow-up (Table 2). 
The quality of evidence (GRADE) for these comparisons was low (Appendix 5).
Secondary outcomes
The bleeding levels changes after treatment were comparable between test and control  groups40,41,43. Likewise, 
no inter-group differences were found in terms of plaque levels  changes40,42.
Another study found that combining NSPT with Vitamin E supplementation improved superoxide dismutase 
activity in  serum43.
Only one study in this group reported explicitly no complications 42, while the others did not provide any 
information about it. The study by Hong reported a significant improvement in the test group of patients’ 
self-reported gingival comfort, as evaluated by one  questionnaire42.
Systemically compromised patients. The literature search did not identify any relevant any relevant RCT where 
NSPT was combined with vitamins in systemically compromised subjects.
Content courtesy of Springer Nature, terms of use apply. Rights reserved
11
Vol.:(0123456789)
Scientific Reports |        (2021) 11:12125  | https://doi.org/10.1038/s41598-021-91506-7
www.nature.com/scientificreports/



































































0.33 0% Low – – – – – – – – – – – –
CAL gain
 − 0.01 
[− 0.07, 
0.05]
0.65 0% Low – – – – – – – – – – – –
Melatonin




 < 1E−4 88% Very low – – – – – – – –
Probiotics
All species
























































































0.31 97% Low – – – – – – – –
Continued
Content courtesy of Springer Nature, terms of use apply. Rights reserved
12
Vol:.(1234567890)
Scientific Reports |        (2021) 11:12125  | https://doi.org/10.1038/s41598-021-91506-7
www.nature.com/scientificreports/
Probiotics. A total of 11 studies tested the adjunctive effect of probiotics to NSPT in healthy patients. Six studies 
used Lactobacillus reuteri  alone24,26,44–47, one combined it with Lactobacillus salivarius and Lactobacillus acido‑
philus48, two studies tested Lactobacillus rhamnosus49,50, one study employed Streptococcus oralis, Streptococcus 
uberis, and Streptococcus rattus51 and one administered Bifidobacterium lactis52.
Healthy patients. 
Primary outcomes
Meta-analysis included all the 11 studies in this group, and the results are presented in Table 2. At 3 months 
a significant benefit in terms of PD reduction and CAL gain was observed when using probiotics (0.30 mm, 
95%CI 0.11 mm to 0.48 mm and 0.21 mm. 95% CI 0.11 mm to 0.31 mm, respectively), while at 6 months no 
significant benefit was observed. The 3 studies that reported data at 12 months indicated an increased reduc-
tion of PD (0.84 mm; 95%CI 0.22 mm to 1.46 mm) and CAL gain (0.70 mm; 95% CI 0.36 mm to 1.04 mm) 
when probiotics were combined with NSPT. At all time points, the quality of evidence (GRADE) was rated 
as low (Appendix 5).
When considering studies that stratified the results based on PD, the use of probiotics seemed to be more 
beneficial in deep sites (PD ≥ 7 mm), although the quality of evidence (GRADE) was rated as very low / low 
(Appendix 5).
A sub-analysis of studies testing L. reuteri alone was performed (Table 2). A significant improvement in terms 
of PD and CAL (0.33 mm; 95% CI 0.08 mm to 0.58 mm and 0.26 mm; 95% CI 0.14 mm to 0.38 mm) was 
observed at 3 months and the quality of evidence (GRADE) for such product was considered as moderate. 
At 6 months no significant differences could be obtained when using or not this specific probiotic combined 
with NSPT.
Secondary outcomes
The adjunctive use of probiotics improved BOP and PI at 3 months (6.85%; 95% CI 3.36% to 10.34% and 5%; 
95% CI 0.80% to 9.21%, respectively) and BOP at 12 months (7.41%; 95% CI 2.34% to 12.49%). However, the 
quality of evidence (GRADE) was rated as low for both parameters (Appendix 5).
When looking at studies testing L. reuteri alone associated with NSPT, a significant improvement in BOP was 
reported (5.41%; 95% CI 0.31% to 10.56%), but the quality of evidence (GRADE) was rated as low (Appendix 
5).
Only one study in this group reported one minor complication in the control group (one patient referred 
unspecified “discomfort”)45.
Systemically compromised patients. The literature search did not identify any relevant any relevant RCT where 
NSPT was combined with probiotics in systemically compromised subjects.
Sub‑antimicrobial dose of tetracycline (SDD). Ten studies tested the systemic administration of sub-antimicro-
bial doses of tetracycline (SDD) as adjunct to  NSPT21–23,25,27,52–57. In one study the authors tested  incyclinide53 
while in all the other studies the authors administered doxycycline, with various regimens. All studies involved 
systemically healthy patients, apart from one study that recruited type 2 diabetic  patients27.
Healthy patients. 
Primary outcomes
A benefit in PD reduction and CAL gain was observed at 3 months when adding SSD to NSPT (0.20 mm; 
95% CI 0.00 mm to 0.40 mm and 0.30 mm; 95% CI 0.19 mm to 0.41 mm, respectively) in systemically healthy 
patients (Table 2), with the quality of evidence (GRADE) rated as very low / low (Appendix 5). The study 
published by Needleman et al.23, not included in the meta-analysis, tested doxycycline on a cohort of smokers, 
without finding any clinical or biochemical markers advantage in the test group.
Table 2.  Summary of the results of the meta-analysis. Bold means significanlty different (from the statistical 
point of view).
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In three studies, the authors provided data stratified on the basis of initial PD. Mohammad et al.21 reported 
a significantly higher PD reduction and CAL gain when administering SDD both in moderate pockets 
(4–6 mm) and in deeper ones, for all timepoints (3, 6, and 9 months). Likewise, in two separate studies on 
large samples of subjects (209 and 227 respectively), it was found that PD reduction and CAL gain were 
significantly improved in the test compared to the control group, with better results in deeper pockets than 
in moderate  ones22,57.
Secondary outcomes
Few studies reported a significantly higher decrease in gingival inflammation when SDD was 
 administered21,22,25,56. Plaque levels tended to decrease in a similar way (without any significant difference) 
between test and control  groups25,53,54.
Three studies reported the occurrence of adverse effects. In particular, one study reported adverse events in 
five subjects belonging to the control group, probably not related to the  treatment23 and another study reported 
that seven subjects in the control group quitted the study due to the occurrence of adverse  events57. Preshaw 
et al.22 indicated a total of 217 and 229 adverse events in the test and control groups, respectively. In the SDD-
treated group the most frequently reported adverse events were headache, influenza and naso-pharyngitis, 
while in the placebo group the most frequently reported adverse events were sensitivity of teeth, headache 
and naso-pharyngitis. No severe adverse events were considered related to the treatment.
Systemically compromised patients. 
Primary outcomes
Gilowsky et al.27 showed a significant difference in PD reduction between diabetic type 2 patients receiving 
SDD and patients receiving the placebo after 3 months from NSPT when considering sites with initial moderate 
disease (PD ≥ 4 mm).
Secondary outcomes
While BOP improved after NSPT, no significant differences were detectable between diabetic type 2 patients 
receiving SDD or  not27. GCF matrix metalloproteinase-8 levels were significantly reduced only in SRP + SDD 
group 3 months after therapy.
Others. One study evaluated the adjunctive administration of Alpha Lipoic Acid (ALA) in 40 (20 per group) 
subjects with periodontitis and type 2 diabetes  mellitus29. The results demonstrated a significant effect of ALA in 
improving both PD and CAL, as well as GI after 3 months of treatment. Moreover, Surapanemi et al.29 reported 
that the administration of ALA after NSPT could reduce the levels of serum resistin and HbA1c in diabetic 
patients.
Discussion
The present systematic review evaluated the effect of the adjunctive systemic administration of HMs on the 
outcomes of NSPT and it indicated, as evaluated by GRADE approach, an overall low/very low quality of evi-
dence for SDD and melatonin in improving PD and/or CAL gain when administered in systemically healthy 
patients. Conflicting evidence is available for probiotics administered in systemically healthy patients, with low 
evidence of a benefit at 3 and 12 months but no significant benefit at 6 months post NSPT. The dosage, posology 
and long-term effect of HMs still need to be clarified. It should be noted that only 5 studies dealt with systemi-
cally compromised patients and they all included type 2 diabetic patients, so no speculation can be done on the 
potential benefit of HMs in patients with underlying medical conditions associated with an altered/exaggerated 
inflammatory response other than diabetes.
In particular, meta-analysis indicated that there is low/very low evidence that the adjunctive use of SDD 
would lead to a significant improvement both in terms of CAL (0.30 mm) and PD (0.20 mm) in the short 
term (3 months), although this benefit cannot be considered as clinically relevant. No meta-analysis could be 
performed for longer healing times, nevertheless few studies suggested a benefit up to 9 months post NSPT, 
particularly in case of deep pockets (≥ 7 mm)25,57,58. Only one study assessed SDD in diabetic type 2 patients and 
it suggested a significant difference in PD reduction between patients receiving SDD and patients receiving the 
placebo after 3 months from NSPT n sites with PD ≥ 4  mm27.
While the use of omega-3 alone did not provide a significant benefit when added to NSPT, the combina-
tion with low-dose aspirin significantly improved both PPD reduction and CAL gain both at 3- and 6-months 
post NSPT as reported in two  studies28,30. It should be noted that the studies testing this combination involved 
patients affected by diabetes type 2, thus suggesting that this particular subgroup of patients might specifically 
benefit from the addition of modulators of the inflammatory response, although the current quality of evidence 
is very low, and we could not perform a meta-analysis. Remarkably, one additional study, not included in the 
review for methodological concerns regarding the allocation method, reported a substantially positive effect of 
the adjunctive assumptions of omega-3 and ASA in a cohort of systemically healthy  subjects59.
When analyzing the use of different probiotic preparations, there was low-grade evidence that they would 
improve PD reduction and CAL gain at 3 (0.30 mm and 0.21 mm, respectively) and 12 months (0.84 mm and 
0.70 mm, respectively) post NSPT in systemically healthy patients, particularly in deep pockets (≥ 7 mm), while 
no benefits were observed at 6 months, thus confirming previous  findings8. A sub-analysis of 6 studies testing L. 
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reuteri alone was performed, and there was moderate evidence of a significant effect for PD reduction and CAL 
gain after three months, but the evidence was judged as low for all other outcomes and time points.
Moreover, 3 studies suggested a benefit in PD reduction when melatonin was combined with NSPT in systemi-
cally healthy patients, however the clinical benefit was limited (0.85 mm) and the overall quality of the available 
evidence was judged as very low. No significant benefit was associated with the use of vitamins and insufficient 
data were available for other HMs. In line with what recently recommended by the EFP S3 level clinical practice 
guideline and considering the well-documented risk of severe adverse events associated with the systemic use 
of bisphosphonates and NSAIDs, it is not recommended to use these systemic HMs to enhance the outcomes 
of NSPT.
Our outcomes corroborated the results of a recent systematic  review8, but also added important additional 
and complementary information in terms of the effect of HMs on early healing (3 months), grade of the evidence 
and role of HMs in the presence of systemic diseases (e.g., diabetes).
The early healing (3 months post NSPT) response after delivery of a HM was considered important to inves-
tigate since it may be less affected by patient’s compliance to oral hygiene instructions and, therefore, might 
provide relevant information on the “true” potential of the modulator.
It is worth highlighting that in this systematic review we performed meta-analysis when ≥ 3 studies inves-
tigating the same HM were available. While a meta-analysis is simply the statistical combination of results 
and there is no fixed number of studies or combined number of individuals that can be used as a threshold to 
decide whether data are warrant statistical  combination60–62, we recognize that some level of caution needs to be 
applied when drawing conclusions based only on few studies, in particular when the studies are heterogeneous. 
Remarkably, besides providing meta-analyses, this systematic review was one of the first in the field of periodon-
tology to include also an assessment of the strength of the evidence for each comparison and for each outcome 
considered according to the GRADE system. As a matter of fact, when elaborating evidence-based treatment 
guidelines, it is of outmost importance to evaluate not only the statistical significance of a summary estimate of 
treatment effect and the effect size, but also the quality and confidence in that estimate. The purpose of GRADE 
is to offer a transparent, user-friendly and pragmatic tool that clearly separates between quality of evidence and 
strength of recommendations and is therefore a valuable system to support clinicians in decision-making about 
 healthcare63 and it has already been adopted by several international associations involved in the development 
of treatment guidelines, such as the World Health Organization, the American College of Physicians and the 
Cochrane  Collaboration19. An insufficient attention to quality of evidence exposes clinicians and researchers 
to the risk of developing inappropriate/misleading guidelines and recommendations that act to the detriment 
rather than to the benefit of their patients.
Overall, the GRADE assessment revealed that the quality of evidence in the investigated field is low or very 
low and such evaluation was mainly due to the significant heterogeneity among studies, differences in treatment 
protocols and risk of bias. In particular, the different dosages administered in the SDD group and the different 
probiotic formulations tested have reduced the scientific evidence for these HMs.
While host modulators can possibly enhance the outcomes of NSPT in all patients, it is reasonable to hypoth-
esize that they might become particularly useful in patients that have an exaggerated/ineffective inflammatory-
immune response because of an underlying medical condition. Diabetes type 2 is an example of multifactorial 
disease in which inflammation plays a crucial role in promoting insulin resistance and the development of long-
term complications and has a well-recognized link with periodontitis, so that periodontitis is even considered its 
 6th most frequent  complication64. Few studies suggested that controlling the inflammatory response with a HM 
that can actively promote inflammation resolution (like alpha lipoic acid or the combination of omega-3 and 
aspirin) or downregulates the activity of matrix metalloproteinases (SDD)27, can enhance the clinical outcomes 
of  NSPT28–30,33. However, the current evidence is too limited to draw any robust conclusion on the potential of 
HMs as adjunct to NSTP in systemically compromised conditions and no data were retrieved from the identified 
papers on the benefit of HMs on other potentially relevant diseases like rheumatoid arthritis or osteoporosis, 
which would warrant further investigations.
When translating the outcomes of this review and meta-analysis to clinical practice, a certain level of caution 
needs to be adopted. While overall no serious adverse events were reported by any of the included studies, the 
recent S3 treatment guidelines for periodontitis stage I–III raised some concerns on the clinical use of SDD for 
periodontal patients due to current health policies on antibiotic stewardship and related public health concerns 
surrounding the global problem of antibiotic  resistance4. Hence, in consideration of this important potential 
issue and the limited clinical efficacy of this HM, it is currently suggested not to use SDD as an adjunct to NSPT.
Moreover, the primary outcomes selected in this systematic review were PPD reduction and CAL gain, which 
are the most commonly reported surrogate outcomes in studies on periodontal treatment, despite they present 
with several  limitations65. Considering that the main goal of periodontal therapy is to achieve shallow pockets 
and absence of bleeding, the percentage of pocket closure could have been possibly a more valuable outcome to 
assess the performance of  HMs66, but only a minority of the selected studies evaluated it. It is also suggested that 
with the aim of developing guidelines for periodontal therapy the proportion of threshold changes such as ≥ 2 mm 
or ≥ 3 mm in clinical attachment levels are preferable rather than mean  changes66, but again only a minority of 
the included studies provided data in this respect. It should be noted that, since the rational of using of HMs has 
to do mainly with the modulation of the exaggerated immune-inflammatory response towards the microbial 
challenge, inflammatory indices (such as bleeding scores and gingival indices) should be taken into consideration 
when assessing the treatment response. Overall, all HMs tended to reduce the levels of inflammation compared 
to the placebo or no treatment, but due to the heterogeneity in the indices measured, meta-analysis could only 
be performed for probiotics and it indicated a significant reduction in BOP at 3 and 12 months (6.85% ad 7.41%, 
respectively) when probiotics were combined with NSPT.
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One of the potential limitations related to the studies included in this systematic review is that they all aggre-
gated patient-level data providing a summary statistical approach (i.e., mean) for PD and CAL changes. While 
this allows to assess an overall effect of the different HMs on the periodontal condition of the patient, it should 
be recognized that periodontitis is most often a site-specific disease, and by aggregating site-level evaluations 
there is the risk of losing important  information67 and diluting the real effect that the HM might have had. In 
this respect, it is interesting to mention that Pelekos et al.68 have recently performed a sub-analysis of site-level 
data sourced from a previously published  study45 where they showed that, while a 4-week administration of L. 
reuteri did not provide benefits on aggregate patient-level outcomes, a significant modest benefit in terms of 
CAL gain could be expected when focusing only on molar sites with PD ≥ 5 mm. Moreover, in these sites the 
relative risk of pocket closure was higher in the probiotic group than in the placebo group (1.7 at 90 days and 
1.6 at 180 days). Likewise, studies that stratified the treatment response to SDD according to the initial PD depth 
showed an enhanced PD reduction and CAL gain when focusing only on pockets that had a baseline PD ≥ 7 
 mm21,22,25,57,58,69,70. It is therefore suggested that future studies testing systemic MDs should perform multilevel 
analyses to assess not only the patient-level but also the site-level response to them. In particular, it would be 
interesting to explore if HMs have a positive impact on the treatment response of particularly challenging sites, 
like deep pockets associated with intrabony defects or furcation involvement. Remarkably, Donos et al.8 have 
shown that locally delivered HMs (namely statins, bisphosphonates and metformin) can significantly improve 
the response to NSPT of deep vertical intrabony defects.
Another limitation that should be mentioned when analyzing the results of the present systematic review is 
that the protocol for NSPT adopted in the different studies was not consistent. While some studies did not pro-
vide details on how the instrumentation was performed, other studies reported a different number of sessions, 
a different length of visits and possibly a different level of experience of the operators. Hence, it is not possible 
to assess if the different NSPT protocols impacted on the clinical outcomes. Moreover, the study populations 
differed in terms of systemic health status, smoking status, age and gender distribution and we cannot make any 
conclusions on how these factors might have influenced the outcomes investigated.
Finally, it is worth to highlight that the great majority of the studies were conducted in a controlled academic/
hospital environment by researchers that possibly had a level of training, skills and attention to NSPT that might 
not reflect the average level of general dentists, so the studies informed more on the efficacy rather than effec-
tiveness of HMs. It would be important in the future to test the most promising HMs at a primary care level to 
assess their effectiveness rather than efficacy.
Conclusions
There is low/very low evidence based on the results of RCTs that the adjunctive use of SDD and melatonin to 
NSPT would lead to a statistically significant improvement in clinical periodontal parameters, while conflicting 
evidence is available on the efficacy of probiotics. Owing to the heterogeneity of the available studies and the 
limited average clinical benefit indicated by the meta-analyses, currently there is no robust evidence to suggest the 
implementation of any of the aforementioned HMs in clinical practice. The potential benefit of HMs in systemi-
cally compromised patients affected by periodontitis needs to be further investigated, as currently there is only 
some limited evidence on type 2 diabetes and none of the identified RCTs dealt with other systemic diseases. In 
particular, the combination of omega-3 and low dose aspirin as an adjunct to NSPT gave promising outcomes 
in type 2 diabetic patients, which need to be conformed by further RCTs.
Future studies controlling for confounding factors and using composite outcomes to define the endpoint of 
therapy are warranted. Moreover, it is recommended that not only the patient level but also as the site-specific 
effect of systemic HMs is clarified.
Data availability
The authors confirm that the data supporting the findings of this study are available within the article or its 
supplementary materials.
Received: 13 April 2021; Accepted: 10 May 2021
References
 1. Cekici, A., Kantarci, A., Hasturk, H. & Van Dyke, T. E. Inflammatory and immune pathways in the pathogenesis of periodontal 
disease. Periodontol. 2000(64), 57–80. https:// doi. org/ 10. 1111/ prd. 12002 (2014).
 2. Hajishengallis, G. & Lamont, R. J. Beyond the red complex and into more complexity: the polymicrobial synergy and dysbiosis 
(PSD) model of periodontal disease etiology. Mol. Oral. Microbiol. 27, 409–419. https:// doi. org/ 10. 1111/j. 2041- 1014. 2012. 00663.x 
(2012).
 3. Hajishengallis, G. The inflammophilic character of the periodontitis-associated microbiota. Mol. Oral. Microbiol. 29, 248–257. 
https:// doi. org/ 10. 1111/ omi. 12065 (2014).
 4. Sanz, M. et al. Treatment of stage I-III periodontitis—the EFP S3 level clinical practice guideline. J. Clin. Periodontol. https:// doi. 
org/ 10. 1111/ jcpe. 13290 (2020).
 5. Van der Weijden, G. A. & Timmerman, M. F. A systematic review on the clinical efficacy of subgingival debridement in the treat-
ment of chronic periodontitis. J. Clin. Periodontol. 29 (Suppl 3), 55–71; discussion 90–51 (2002).
 6. Cobb, C. M. Clinical significance of non-surgical periodontal therapy: an evidence-based perspective of scaling and root planing. 
J. Clin. Periodontol. 29(Suppl 2), 6–16 (2002).
 7. Graziani, F., Karapetsa, D., Alonso, B. & Herrera, D. Nonsurgical and surgical treatment of periodontitis: how many options for 
one disease?. Periodontol. 2000(75), 152–188. https:// doi. org/ 10. 1111/ prd. 12201 (2017).
 8. Donos, N. et al. The adjunctive use of host modulators in non-surgical periodontal therapy. A systematic review of randomized, 
placebo-controlled clinical studies. J. Clin. Periodontol. 47(22), 199–238. https:// doi. org/ 10. 1111/ jcpe. 13232 (2020).
Content courtesy of Springer Nature, terms of use apply. Rights reserved
16
Vol:.(1234567890)
Scientific Reports |        (2021) 11:12125  | https://doi.org/10.1038/s41598-021-91506-7
www.nature.com/scientificreports/
 9. Higgins, J. P. T. & Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions 2nd edn. (Wiley-Blackwell, 
2020).
 10. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: 
the PRISMA statement. J. Clin. Epidemiol. 62, 1006–1012. https:// doi. org/ 10. 1016/j. jclin epi. 2009. 06. 005 (2009).
 11. Ainamo, J. & Bay, I. Problems and proposals for recording gingivitis and plaque. Int. Dent. J. 25, 229–235 (1975).
 12. Loe, H. & Silness, J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol. Scand. 21, 533–551. https:// doi. 
org/ 10. 3109/ 00016 35630 90112 40 (1963).
 13. Silness, J. & Loe, H. Periodontal disease in pregnancy. Ii. Correlation between oral hygiene and periodontal condtion. Acta Odontol. 
Scand. 22, 121–135. https:// doi. org/ 10. 3109/ 00016 35640 89939 68 (1964).
 14. Turesky, S., Gilmore, N. D. & Glickman, I. Reduced plaque formation by the chloromethyl analogue of victamine C. J. Periodontol. 
41, 41–43. https:// doi. org/ 10. 1902/ jop. 1970. 41. 41. 41 (1970).
 15. Follmann, D., Elliott, P., Suh, I. & Cutler, J. Variance imputation for overviews of clinical trials with continuous response. J. Clin. 
Epidemiol. 45, 769–773. https:// doi. org/ 10. 1016/ 0895- 4356(92) 90054-q (1992).
 16. Abrams, K. R., Gillies, C. L. & Lambert, P. C. Meta-analysis of heterogeneously reported trials assessing change from baseline. Stat. 
Med. 24, 3823–3844. https:// doi. org/ 10. 1002/ sim. 2423 (2005).
 17. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials 7, 177–188 (1986).
 18. Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J. & Welch, V. A. (editors). Cochrane handbook for systematic 
review of interventions, 2nd Edition. (John Wiley & Sons, Chichester (UK), 2019).
 19. Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336, 
924–926. https:// doi. org/ 10. 1136/ bmj. 39489. 470347. AD (2008).
 20. Rocha, M. L., Malacara, J. M., Sanchez-Marin, F. J., de la Torre, C. J. V. & Fajardo, M. E. Effect of alendronate on periodontal disease 
in postmenopausal women: a randomized placebo-controlled trial. J. Periodontol. 75, 1579–1585. https:// doi. org/ 10. 1902/ jop. 2004. 
75. 12. 1579 (2004).
 21. Mohammad, A. R. et al. Adjunctive subantimicrobial dose doxycycline in the management of institutionalised geriatric patients 
with chronic periodontitis. Gerodontology 22, 37–43. https:// doi. org/ 10. 1111/j. 1741- 2358. 2004. 00044.x (2005).
 22. Preshaw, P. M. et al. Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with peri-
odontal disease. J. Periodontol. 79, 440–452. https:// doi. org/ 10. 1902/ jop. 2008. 070375 (2008).
 23. Needleman, I. et al. A randomized-controlled trial of low-dose doxycycline for periodontitis in smokers. J. Clin. Periodontol. 34, 
325–333. https:// doi. org/ 10. 1111/j. 1600- 051X. 2007. 01058.x (2007).
 24. Theodoro, L. H. et al. Effects of lactobacillus reuteri as an adjunct to the treatment of periodontitis in smokers: randomised clinical 
trial. Benef. Microb. 10, 375–384. https:// doi. org/ 10. 3920/ BM2018. 0150 (2019).
 25. Emingil, G., Gürkan, A., Atilla, G., Berdeli, A. & Çnarcik, S. Adjunctive low-dose doxycycline therapy effect on clinical parameters 
and gingival crevicular fluid tissue plasminogen activator levels in chronic periodontitis. Inflamm. Res. 55, 550–558. https:// doi. 
org/ 10. 1007/ s00011- 006- 6074-2 (2006).
 26. Vohra, F. et al. Effectiveness of scaling and root planing with and without adjunct probiotic therapy in the treatment of chronic 
periodontitis among shamma users and non-users: a randomized controlled trial. J. Periodontol. https:// doi. org/ 10. 1002/ JPER. 
19- 0464 (2020).
 27. Gilowski, Ł et al. Efficacy of short-term adjunctive subantimicrobial dose doxycycline in diabetic patients—randomized study. 
Oral Dis. 18, 763–770. https:// doi. org/ 10. 1111/j. 1601- 0825. 2012. 01943.x (2012).
 28. Elwakeel, N. M. & Hazaa, H. H. Effect of omega 3 fatty acids plus low-dose aspirin on both clinical and biochemical profiles of 
patients with chronic periodontitis and type 2 diabetes: a randomized double blind placebo-controlled study. J. Periodontal Res. 
50, 721–729. https:// doi. org/ 10. 1111/ jre. 12257 (2015).
 29. Surapaneni, K. et al. Efficacy of systemic administration of alpha lipoic acid and scaling and root planning in patients with chronic 
periodontitis and type 2 diabetes mellitus—a randomised controlled trial. J. Clin. Diagn. Res. 12, ZC01–ZC05 (2018).
 30. Dos Santos, N. C. C. et al. Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and 
type 2 diabetes mellitus. Randomized clinical trial. J. Periodontol. https:// doi. org/ 10. 1002/ JPER. 19- 0613 (2020).
 31. Deore, G. D. et al. Omega 3 fatty acids as a host modulator in chronic periodontitis patients: a randomised, double-blind, palcebo-
controlled, clinical trial. J. Periodontal Implant Sci. 44, 25–32. https:// doi. org/ 10. 5051/ jpis. 2014. 44.1. 25 (2014).
 32. Umrania, V. V., Deepika, P. C. R. & Kulkarni, M. Evaluation of dietary supplementation of omega-3 polyunsaturated fatty acids 
as an adjunct to scaling and root planing on salivary interleukin-1beta levels in patients with chronic periodontitis: a clinico-
immunological study. J. Indian Soc. Periodontol. 21, 386–390. https:// doi. org/ 10. 4103/ jisp. jisp_ 16_ 16 (2017).
 33. Rampally, P., Koduganti, R. R., Ganapathi, S. N., Panthula, V. R. & Surya, P. J. Comparison of effectiveness of low-dose aspirin 
versus omega-3 fatty acids as adjuvants to nonsurgical periodontal therapy in type II diabetic patients with chronic periodontitis. 
J. Indian Soc. Periodontol. 23, 249–256. https:// doi. org/ 10. 4103/ jisp. jisp_ 528_ 18 (2019).
 34. Keskiner, I., Saygun, I., Bal, V., Serdar, M. & Kantarci, A. Dietary supplementation with low-dose omega-3 fatty acids reduces 
salivary tumor necrosis factor-alpha levels in patients with chronic periodontitis: a randomized controlled clinical study. J. Peri‑
odontal Res. 52, 695–703. https:// doi. org/ 10. 1111/ jre. 12434 (2017).
 35. Yen, C. A. et al. The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis. J. Periodontol. 79, 104–113. 
https:// doi. org/ 10. 1902/ jop. 2008. 070271 (2008).
 36. El-Sharkawy, H., Elmeadawy, S., Elshinnawi, U. & Anees, M. Is dietary melatonin supplementation a viable adjunctive therapy for 
chronic periodontitis?—a randomized controlled clinical trial. J. Periodontal Res. 54, 190–197. https:// doi. org/ 10. 1111/ jre. 12619 
(2019).
 37. Chitsazi, M., Faramarzie, M., Sadighi, M., Shirmohammadi, A. & Hashemzadeh, A. Effects of adjective use of melatonin and vita-
min C in the treatment of chronic periodontitis: a randomized clinical trial. J. Dent. Res. Dent. Clin. Dent. Prospect. 11, 236–240. 
https:// doi. org/ 10. 15171/ joddd. 2017. 041 (2017).
 38. Tinto, M., Sartori, M., Pizzi, I., Verga, A. & Longoni, S. Melatonin as host modulating agent supporting nonsurgical periodontal 
therapy in patients affected by untreated severe periodontitis: a preliminary randomized, triple-blind, placebo-controlled study. 
J. Periodontal Res. 55, 61–67. https:// doi. org/ 10. 1111/ jre. 12686 (2020).
 39. Graziani, F. et al. Lack of short-term adjunctive effect of systemic neridronate in non-surgical periodontal therapy of advanced 
generalized chronic periodontitis: an open label-randomized clinical trial. J. Clin. Periodontol. 36, 419–427. https:// doi. org/ 10. 
1111/j. 1600- 051X. 2009. 01388.x (2009).
 40. Sulaiman, A. E. A. & Shehadeh, R. M. H. Assessment of total antioxidant capacity and the use of vitamin C in the treatment of 
non-smokers with chronic periodontitis. J. Periodontol. 81, 1547–1554. https:// doi. org/ 10. 1902/ jop. 2010. 100173 (2010).
 41. Chapple, I. L. et al. Adjunctive daily supplementation with encapsulated fruit, vegetable and berry juice powder concentrates and 
clinical periodontal outcomes: a double-blind RCT. J. Clin. Periodontol. 39, 62–72. https:// doi. org/ 10. 1111/j. 1600- 051X. 2011. 
01793.x (2012).
 42. Hong, J. Y. et al. A randomized, double-blind, placebo-controlled multicenter study for evaluating the effects of fixed-dose combi-
nations of vitamin C, vitamin E, lysozyme, and carbazochrome on gingival inflammation in chronic periodontitis patients. BMC 
Oral Health 19, 40. https:// doi. org/ 10. 1186/ s12903- 019- 0728-2 (2019).
Content courtesy of Springer Nature, terms of use apply. Rights reserved
17
Vol.:(0123456789)
Scientific Reports |        (2021) 11:12125  | https://doi.org/10.1038/s41598-021-91506-7
www.nature.com/scientificreports/
 43. Singh, N., Narula, S. C., Sharma, R. K., Tewari, S. & Sehgal, P. K. Vitamin E supplementation, superoxide dismutase status, and 
outcome of scaling and root planing in patients with chronic periodontitis: a randomized clinical trial. J. Periodontol. 85, 242–249. 
https:// doi. org/ 10. 1902/ jop. 2013. 120727 (2014).
 44. Ince, G. et al. Clinical and biochemical evaluation of lozenges containing Lactobacillus reuteri as an adjunct to non-surgical peri-
odontal therapy in chronic periodontitis. J. Periodontol. 86, 746–754. https:// doi. org/ 10. 1902/ jop. 2015. 140612 (2015).
 45. Pelekos, G., Ho, S. N., Acharya, A., Leung, W. K. & McGrath, C. A double-blind, paralleled-arm, placebo-controlled and rand-
omized clinical trial of the effectiveness of probiotics as an adjunct in periodontal care. J. Clin. Periodontol. 46, 1217–1227. https:// 
doi. org/ 10. 1111/ jcpe. 13191 (2019).
 46. Tekce, M. et al. Clinical and microbiological effects of probiotic lozenges in the treatment of chronic periodontitis: a 1-year follow-
up study. J. Clin. Periodontol. 42, 363–372. https:// doi. org/ 10. 1111/ jcpe. 12387 (2015).
 47. Teughels, W. et al. Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: 
a randomized placebo-controlled study. J. Clin. Periodontol. 40, 1025–1035. https:// doi. org/ 10. 1111/ jcpe. 12155 (2013).
 48. Soares, L. G., de Carvalho, E. B. & Tinoco, E. M. B. Clinical effect of Lactobacillus on the treatment of severe periodontitis and 
halitosis: a double-blinded, placebo-controlled, randomized clinical trial. Am. J. Dent. 32, 9–13 (2019).
 49. Morales, A. et al. Clinical effects of Lactobacillus rhamnosus in non-surgical treatment of chronic periodontitis: a randomized 
placebo-controlled trial with 1-year follow-up. J. Periodontol. 87, 944–952. https:// doi. org/ 10. 1902/ jop. 2016. 150665 (2016).
 50. Morales, A. et al. Microbiological and clinical effects of probiotics and antibiotics on nonsurgical treatment of chronic periodon-
titis: a randomized placebo- controlled trial with 9-month follow-up. J. Appl. Oral Sci. 26, e20170075. https:// doi. org/ 10. 1590/ 
1678- 7757- 2017- 0075 (2018).
 51. Laleman, I. et al. The effect of a streptococci containing probiotic in periodontal therapy: a randomized controlled trial. J. Clin. 
Periodontol. 42, 1032–1041. https:// doi. org/ 10. 1111/ jcpe. 12464 (2015).
 52. Invernici, M. M. et al. Effects of Bifidobacterium probiotic on the treatment of chronic periodontitis: a randomized clinical trial. 
J. Clin. Periodontol. 45, 1198–1210. https:// doi. org/ 10. 1111/ jcpe. 12995 (2018).
 53. Alyousef, A. A., Divakar, D. D., Muzaheed, M. & Al-Kheraif, A. A. Chemically modified tetracyclines an emerging host modulator 
in chronic periodontitis patients: a randomized, double-blind, placebo-controlled, clinical trial. Microb. Pathog. 110, 279–284. 
https:// doi. org/ 10. 1016/j. micpa th. 2017. 07. 002 (2017).
 54. Gorska, R. & Nedzi-Gora, M. The effects of the initial treatment phase and of adjunctive low-dose doxycycline therapy on clinical 
parameters and MMP-8, MMP-9, and TIMP-1 levels in the saliva and peripheral blood of patients with chronic periodontitis. 
Arch. Immunol. Ther. Exp. 54, 419–426. https:// doi. org/ 10. 1007/ s00005- 006- 0047-6 (2006).
 55. Lee, H.-M. et al. Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis 
patients is enhanced when combined with a non-steroidal anti-inflammatory drug. J. Periodontol. 75, 453–463. https:// doi. org/ 
10. 1902/ jop. 2004. 75.3. 453 (2004).
 56. Parvu, A. E., Alb, S. F., Craciun, A. & Taulescu, M. Efficacy of subantimicrobial-dose doxycycline against nitrosative stress in 
chronic periodontitis. Acta Pharmacol. Sin. 34, 247–254. https:// doi. org/ 10. 1038/ aps. 2012. 129 (2013).
 57. Preshaw, P. M. et al. Subantimicrobial dose doxycycline enhances the efficacy of scaling and root planing in chronic periodontitis: 
a multicenter trial. J. Periodontol. 75, 1068–1076. https:// doi. org/ 10. 1902/ jop. 2004. 75.8. 1068 (2004).
 58. Caton, J. G. et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients 
with adult periodontitis. J. Periodontol. 71, 521–532. https:// doi. org/ 10. 1902/ jop. 2000. 71.4. 521 (2000).
 59. El-Sharkawy, H. et al. Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 fatty acids 
and low-dose aspirin. J. Periodontol. 81, 1635–1643. https:// doi. org/ 10. 1902/ jop. 2010. 090628 (2010).
 60. Bown, M. J. & Sutton, A. J. Quality control in systematic reviews and meta-analyses. Eur. J. Vasc. Endovasc. Surg. 40, 669–677. 
https:// doi. org/ 10. 1016/j. ejvs. 2010. 07. 011 (2010).
 61. Deeks, J. J., Higgins, J. P. T. & Altman, D. G. in Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated 
July 2019) (eds. Higgins, J. P. T., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A.) (2019).
 62. Valentine, J. C., Pigott, T. D. & Rothstein, H. R. How many studies do you need?: A primer on statistical power for meta-analysis. 
J. Educ. Behav. Stat. 35, 215–247. https:// doi. org/ 10. 3102/ 10769 98609 346961 (2010).
 63. Terracciano, L., Brozek, J., Compalati, E. & Schunemann, H. GRADE system: new paradigm. Curr. Opin. Allergy Clin. Immunol. 
10, 377–383. https:// doi. org/ 10. 1097/ ACI. 0b013 e3283 3c148b (2010).
 64. Loe, H. Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care 16, 329–334 (1993).
 65. Hujoel, P. P. Endpoints in periodontal trials: the need for an evidence-based research approach. Periodontol. 2000(36), 196–204. 
https:// doi. org/ 10. 1111/j. 1600- 0757. 2004. 03681.x (2004).
 66. Loos, B. G. & Needleman, I. Endpoints of active periodontal therapy. J. Clin. Periodontol. https:// doi. org/ 10. 1111/ jcpe. 13253 (2020).
 67. Nomura, Y. et al. Site-level progression of periodontal disease during a follow-up period. PLoS ONE 12, e0188670. https:// doi. org/ 
10. 1371/ journ al. pone. 01886 70 (2017).
 68. Pelekos, G. et al. Effects of adjunctive probiotic L. reuteri lozenges on S/RSD outcomes at molar sites with deep pockets. J. Clin. 
Periodontol. https:// doi. org/ 10. 1111/ jcpe. 13329 (2020).
 69. Novak, M. J., Johns, L. P., Miller, R. C. & Bradshaw, M. H. Adjunctive benefits of subantimicrobial dose doxycycline in the manage-
ment of severe, generalized, chronic periodontitis. J. Periodontol. 73, 762–769. https:// doi. org/ 10. 1902/ jop. 2002. 73.7. 762 (2002).
 70. Gurkan, A., Çnarcik, S. & Huseyinov, A. Adjunctive subantimicrobial dose doxycycline: effect on clinical parameters and gingival 
crevicular fluid transforming growth factor-beta levels in severe, generalized chronic periodontitis. J. Clin. Periodontol. 32, 244–253. 
https:// doi. org/ 10. 1111/j. 1600- 051X. 2005. 00663.x (2005).
Author contributions
All authors contributed to the study conception and design. S.C., E.C. and A.A. performed the literature search 
and data analysis. The first draft of the manuscript was written by S.C. and E.C. and all authors commented on 
previous versions of the manuscript. N.D. and L.F. critically revised the work. All authors read and approved 
the final manuscript.
Competing interests 
The authors declare no competing interests.
Additional information
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 
10. 1038/ s41598- 021- 91506-7.
Correspondence and requests for materials should be addressed to S.C.
Reprints and permissions information is available at www.nature.com/reprints.
Content courtesy of Springer Nature, terms of use apply. Rights reserved
18
Vol:.(1234567890)
Scientific Reports |        (2021) 11:12125  | https://doi.org/10.1038/s41598-021-91506-7
www.nature.com/scientificreports/
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
© The Author(s) 2021









Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”). 
Springer Nature supports a reasonable amount of sharing of  research papers by authors, subscribers and authorised users (“Users”), for small-
scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By
accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these
purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial. 
These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal
subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription
(to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will
apply. 
We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within
ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not
otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as
detailed in the Privacy Policy. 
While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may
not: 
 
use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access
control;
use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is
otherwise unlawful;
falsely or misleadingly imply or suggest endorsement, approval , sponsorship, or association unless explicitly agreed to by Springer Nature in
writing;
use bots or other automated methods to access the content or redirect messages
override any security feature or exclusionary protocol; or
share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal
content.
 
In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue,
royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal
content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any
other, institutional repository. 
These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or
content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature
may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved. 
To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied
with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law,
including merchantability or fitness for any particular purpose. 
Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed
from third parties. 
If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not
expressly permitted by these Terms, please contact Springer Nature at 
 
onlineservice@springernature.com
 
